SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 3:00 p.m. ET. A live webcast of the event will be available in the Investors se ...

Summary of Maze Therapeutics FY Conference Call Company Overview - **Company**: Maze Therapeutics (NasdaqGM:MAZE) - **Industry**: Biotechnology, focusing on kidney disease and metabolic disorders - **CEO**: Jason Coloma - **Conference**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 12, 2026 Key Points Industry Context - **Kidney Disease Prevalence**: 37 million people in the U.S. suffer from kidney disease, which is the ninth leading cause of death globally [3][29] - **Lack of Innovation**: There are currently no approved precision medicines for kidney disease, highlighting a significant unmet medical need [3][10] Pipeline and Product Development - **MZE829**: Targeting APOL1-mediated kidney disease - **Proof-of-Concept Data**: Expected by the end of Q1 2026 [4][5] - **Patient Population**: Approximately 250,000 individuals in the U.S. could benefit, with 60% not having diabetes [6][10] - **Mechanism**: Aims to block harmful cellular processes caused by APOL1 overexpression [12][13] - **Phase 2B/3 Study**: Planning to initiate if proof-of-concept data is positive, focusing on a 30% reduction in UACR (urine albumin-to-creatinine ratio) [18][42] - **MZE782**: For phenylketonuria (PKU) and chronic kidney disease (CKD) - **PKU Patient Population**: Approximately 60,000 individuals in key geographies, with many unable to benefit from existing therapies [21][22] - **Mechanism**: Aims to reduce toxic accumulation of phenylalanine without relying on enzyme presence, potentially benefiting all PKU patients [22][23] - **Phase 2 Study**: Expected to start by mid-2026 for PKU, with CKD studies planned for the second half of 2026 [28][29] Financial Position - **Capital Position**: Strong, with operating capital secured until 2028, allowing for the support of near-term milestones and studies [5][39] - **Funding Milestones**: Includes reporting data from the Horizon study, initiating PKU proof-of-concept, and advancing CKD programs [51] Market Dynamics - **Current Treatments**: Existing therapies for kidney disease, such as SGLT2 inhibitors, have high discontinuation rates (over 40%) due to side effects [30][29] - **Strategic Positioning**: MZE782 may complement or replace SGLT2 inhibitors, providing a new treatment option for patients who do not respond well to current therapies [30][38] Future Outlook - **Vision**: To build a next-generation precision medicines company focused on kidney and metabolic diseases, leveraging genetic insights to develop best-in-class therapies [38][39] - **Upcoming Data**: Anticipated updates on MZE829 and MZE782 will be crucial for investor confidence and future development plans [40][51] Additional Insights - **Patient Impact**: The goal is to significantly improve the quality of life for patients suffering from kidney diseases and metabolic disorders through innovative therapies [19][38] - **Regulatory Path**: Clear registrational paths for both MZE829 and MZE782 are being established, with a focus on clinically meaningful endpoints [48][49] This summary encapsulates the critical aspects of Maze Therapeutics' conference call, highlighting the company's strategic focus, product pipeline, financial health, and the broader context of kidney disease treatment.

Lumexa Imaging FY Conference Summary Company Overview - **Company Name**: Lumexa Imaging (NasdaqGS:LMRI) - **Industry**: Diagnostic Imaging - **Market Size**: $140 billion Total Addressable Market (TAM) growing at a 4% CAGR; Outpatient sector at $33 billion TAM growing at a 7% CAGR [7][22] Key Points Industry Dynamics - Diagnostic imaging is a dynamic industry driven by an aging population and advancements in treatment paradigms requiring advanced imaging technologies such as MRI, CT, and PET scans [7][22] - The outpatient imaging sector is experiencing significant growth, with a shift towards lower-cost service centers [22][18] Company Positioning - Lumexa Imaging is the second largest platform in the outpatient imaging space with 188 sites across 13 states, focusing on high-growth markets [7][8] - The company operates a scalable model with a strong joint venture partnership strategy, having completed 44 de novos since inception, including a record nine in the past year [9][12] Financial Metrics - Advanced imaging accounts for 63% of revenue and 36% of volume, indicating a premium revenue model [13][27] - The company has a 97% patient satisfaction rate and an NPS of 91, significantly higher than industry benchmarks [12][15] - Revenue from outpatient imaging centers constitutes over 80% of total revenue and EBITDA [10][12] Growth Strategy - Lumexa aims to continue expanding through de novos and acquisitions, targeting 8-10 new centers annually [9][50] - The company emphasizes same-store growth by maximizing schedules and building referral relationships [48][49] - There is a focus on leveraging advanced technology, including AI, to enhance operational efficiency and patient care [10][33] Joint Venture Model - The joint venture model with health systems allows for shared capital expenditures and operational efficiencies, differentiating Lumexa from competitors [51][52] - The company has identified over 100 potential health system partners across top markets, many of whom currently lack imaging partnerships [43] Labor Market and Staffing - Lumexa benefits from a favorable labor market for radiologists and technologists, with better retention rates than industry averages [53] - The company provides flexibility and job satisfaction for staff, contributing to lower turnover [53] Future Outlook - The company is focused on maintaining a strong balance sheet while pursuing growth opportunities, with a commitment to transparency and communication with stakeholders [49][56] - Investors are expected to appreciate the consistency and quality of Lumexa's growth as it continues to establish itself as a leading outpatient imaging provider [55] Additional Insights - The outpatient imaging industry remains highly fragmented, with Lumexa and its largest competitor, RadNet, accounting for less than 10% of the market [25] - The company’s operational model allows for quick scalability and adaptability in response to market demands [30][41] - Lumexa's strategic partnerships and technology investments are designed to enhance patient experience and operational efficiency, positioning the company for sustained growth [34][36]

Core Viewpoint - Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases, with a presentation scheduled at the J.P. Morgan Healthcare Conference [1]. Company Overview - Maze Therapeutics utilizes human genetics to create novel small molecule precision medicines targeting kidney and metabolic diseases, including obesity [3]. - The company operates its Compass™ platform to identify genetically validated targets, integrating variant discovery and functionalization to advance small molecule programs with first- or best-in-class potential [3]. - The pipeline includes MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease, and MZE782, a SLC6A19 inhibitor advancing to Phase 2 for phenylketonuria and chronic kidney disease [3]. - Maze Therapeutics is headquartered in South San Francisco [3].

Summary of Maze Therapeutics Conference Call Company Overview - **Company**: Maze Therapeutics (NasdaqGM:MAZE) - **Focus**: Development of small molecules targeting chronic kidney disease and metabolic diseases using a genetics approach [1] Industry Context - **Chronic Kidney Disease**: Affects over 800 million individuals globally and is the ninth leading cause of death [1] - **APOL1-mediated Kidney Disease**: At least 1 million individuals in the U.S. could benefit from targeted therapies [2] Key Programs and Developments MZE829 for APOL1-mediated Kidney Disease - **Phase Two Enrollment**: Ongoing with intent to present clinical proof of concept data in Q1 2026 [2][3] - **Target Population**: Focus on broad AMKD patients, including those with and without diabetes [2][7] - **Mechanism of Action**: Dual mechanism targeting the APOL1 gene, differentiating from other compounds [9][10] - **Clinical Proof of Concept Goal**: Aiming for a 30% reduction in UACR relative to baseline [12][26] MZE782 for Phenylketonuria (PKU) - **Phase Two Initiation**: Planned for 2026, targeting a broad spectrum of PKU patients [13][15] - **Clinical Proof of Concept**: Recent data showed a 40-fold increase in urinary Phe excretion, indicating strong pharmacodynamic response [18] SLC6A19 in Chronic Kidney Disease - **Potential Impact**: Identified genetic relationships that could lead to new treatment options, potentially becoming a new standard in kidney disease management [19][20] - **Comparative Efficacy**: Demonstrated superior efficacy in reducing proteinuria compared to SGLT2 inhibitors [21][22] Financial and Strategic Position - **Capitalization**: Successfully completed financing in September, positioning the company to deliver on upcoming data catalysts [27] - **Vision**: Aim to become a leading precision medicine company in kidney and metabolic diseases, with ongoing development of additional small molecules [28][29] Additional Insights - **Demographics of APOL1 Kidney Disease**: Disproportionately affects younger individuals, particularly in the Black community, with faster progression to end-stage renal disease [5][6] - **Regulatory Landscape**: Evolving understanding of kidney disease treatment pathways, with plans for pivotal studies based on upcoming data [5][26] - **Collaboration Potential**: Opportunities for partnerships to advance additional programs, as demonstrated with the Pompe program [29]

Core Insights - Maze Therapeutics has reported positive first-in-human results from the Phase 1 trial of MZE782, indicating its potential as a best-in-class therapy for phenylketonuria (PKU) and a first-in-class treatment for chronic kidney disease (CKD) [2][4][7] - The company is actively enrolling patients in the Phase 2 HORIZON trial of MZE829 for APOL1-mediated kidney disease (AMKD), with topline data expected by the end of Q1 2026 [2][6] - Maze Therapeutics has a strong financial position with $383.9 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2028 [9][20] Program Progress and Anticipated Milestones - MZE829 is being developed as a treatment for AMKD, which affects over one million people in the U.S. [3] - MZE782 targets the solute transporter SLC6A19 and aims to reduce plasma phenylalanine levels in PKU and proteinuria in CKD, with Phase 2 trials planned for 2026 [4][7] Recent Corporate Highlights - In October 2025, Maze appointed Hervé Hoppenot as chairman of its board of directors [5] - The company announced an oversubscribed private placement in September 2025, raising approximately $150 million [16] Financial Performance - For Q3 2025, Maze reported a net loss of $30.1 million, compared to a net loss of $24.8 million in Q3 2024 [13] - Research and development expenses increased to $25.2 million for Q3 2025, up from $19.9 million in Q3 2024, reflecting higher clinical trial costs [11] - General and administrative expenses rose to $7.8 million for Q3 2025, compared to $6.9 million in Q3 2024 [12]

Core Insights - Maze Therapeutics is presenting seven studies at the American Society of Nephrology's Kidney Week, focusing on their lead programs MZE782 and MZE829, which target chronic kidney disease (CKD) and phenylketonuria (PKU) [1][2][3] Group 1: Company Overview - Maze Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision medicines for kidney and metabolic diseases [1][7] - The company utilizes its Compass platform to pursue genetically validated targets, integrating variant discovery and functionalization [7] Group 2: Product Pipeline - MZE782 is an oral SLC6A19 inhibitor aimed at treating PKU and CKD, showing a strong safety profile and potential to improve kidney function in Phase 1 trials [2][6] - MZE829 is an oral APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), which affects over one million people in the U.S. [2][4] - The HORIZON trial for MZE829 is currently enrolling patients and aims to provide initial topline results in Q1 2026 [5] Group 3: Research Presentations - Presentations at ASN include studies on the genetic variants of APOL1 in kidney disease, the effects of small molecule inhibitors on dysfunctional signaling, and the impact of SLC6A19 variants on kidney function [3][4] - Specific presentation titles include studies on APOL1 risk variants, SLC6A19 inhibition, and pharmacokinetics of MZE782 [3]

Core Insights - Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases, including obesity [2] - The company will participate in four upcoming investor conferences, providing live webcasts and archived presentations [1][3] Company Overview - Maze Therapeutics utilizes human genetics to create novel small molecule precision medicines, guided by its Compass™ platform [2] - The company's leading pipeline products include MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease, and MZE782, a SLC6A19 inhibitor advancing to Phase 2 for phenylketonuria and chronic kidney disease [2] Upcoming Events - The company will engage in the following investor conferences: - Guggenheim 2nd Annual Healthcare Innovation Conference on November 11, 2025, at 9:30 a.m. ET [3] - TD Cowen Immunology & Inflammation Summit on November 13, 2025, at 2:00 p.m. ET [3] - Jefferies Global Healthcare Conference in London on November 20, 2025, at 12:00 p.m. GMT / 7:00 a.m. ET [3] - 8th Annual Evercore Healthcare Conference on December 3, 2025, at 10:25 a.m. ET [3]

Core Insights - The biotech sector is experiencing significant momentum, with many clinical-stage and commercial biopharma stocks reaching new 52-week highs due to breakthrough trial data, strategic deals, and earnings surprises [1] Company Summaries - **Metsera Inc. (MTSR)**: A clinical-stage biopharmaceutical company focused on developing hormone analog peptides for obesity and related metabolic diseases. Recently, Novo Nordisk made a $9 billion unsolicited acquisition proposal, which Metsera's board considers superior to its existing agreement with Pfizer [2][3]. Metsera announced positive Phase 2b results for its GLP-1 receptor agonist MET-097i, showing up to 14.1% weight loss after 28 weeks, supporting Phase 3 initiation in late 2025 [4]. The stock rose from $32.35 to a 52-week high of $66.10, a gain of 104.3% [5]. - **Indivior Plc (INDV)**: Develops buprenorphine-based therapies for opioid dependence. The company reported Q3 net income of $42 million, up from $22 million a year ago, with adjusted earnings of $93 million, exceeding Wall Street's expectations [6][7]. The stock increased from $20.86 to a 52-week high of $30.55, reflecting a 46.5% gain [7]. - **Insmed Inc. (INSM)**: Focused on therapies for serious and rare diseases, Insmed reported a Q3 net loss of $370 million but saw net product revenue rise to $142.3 million from $93.4 million last year [8][9]. The company raised its full-year 2025 revenue guidance for ARIKAYCE to $420 million - $430 million, indicating 15% - 18% growth year-over-year [10]. The stock surged from $76.54 to a 52-week high of $194.70, marking a 154.4% gain [10]. - **Ventyx Biosciences Inc. (VTYX)**: A clinical-stage biotech company developing therapies for autoimmune and neurodegenerative diseases. Ventyx reported positive Phase 2 results for its NLRP3 inhibitor VTX3232, showing strong safety and tolerability [11][13]. The stock rose from $3.01 to a 52-week high of $8.52, a gain of over 183% [14]. - **Inhibrx Biosciences Inc. (INBX)**: Focuses on oncology and rare diseases, announcing positive topline results from its ChonDRAgon study for ozekibart in chondrosarcoma [15]. The stock increased from $18.35 to a 52-week high of $83.78, representing a gain of 356.6% [16]. - **ABIVAX Société Anonyme (ABVX)**: Developing therapies for chronic inflammatory diseases, ABIVAX presented positive Phase 3 data for obefazimod in ulcerative colitis [17]. The stock rose from $7.83 to an all-time high of $106.73, marking a significant gain of 1263% [18]. - **Arrowhead Pharmaceuticals Inc. (ARWR)**: Developing RNAi-based therapies, Arrowhead finalized a licensing agreement with Novartis for ARO-SNCA, with financial terms including a $200 million upfront payment [19][20][21]. The stock increased from $29.70 to a 52-week high of $43.33, representing a gain of over 45% [21]. - **Kodiak Sciences Inc. (KOD)**: Focused on retinal diseases, Kodiak announced positive Phase 1b data for KSI-101, showing significant vision improvements [22][23][24]. The stock climbed from $8.98 to a 52-week high of $21.17, delivering a 135.7% gain [22]. - **Arcutis Biotherapeutics Inc. (ARQT)**: Focused on dermatological treatments, Arcutis reported Q3 net income of $7.4 million, a turnaround from a net loss last year, with revenue up 122% year-over-year [25][26]. The stock rose from $14.99 to a 52-week high of $27.08, representing a gain of over 80% [27]. - **Maze Therapeutics Inc. (MAZE)**: Developing precision therapies for various diseases, Maze announced positive Phase 1 results for MZE782 and secured $150 million in a private placement [28][29]. The stock rose from $11.21 to a new 52-week high of $34.29, returning a gain of 206% [29]. - **Supernus Pharmaceuticals Inc. (SUPN)**: Focused on CNS disorders, Supernus is expected to report Q3 earnings of $0.82 per share and revenue of $180.22 million [30][31]. The stock increased from $38.21 to a 52-week high of $57.65, representing a gain of over 50% [31].

Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAZE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Table of Contents As filed with the Securities and Exchange Commission on October 17, 2025. Jason Coloma, Ph.D. Chief Executive Officer 171 Oyster Point Blvd., Suite 300 South San Francisco, California ...